Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Stephen Joseph Balevic

Associate Professor of Pediatrics
Pediatrics, Rheumatology
2301 Erwin Rd, Durham, NC 27710
2301 Erwin Rd, Durham, NC 27710

Selected Grants


Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2021 - 2026

Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025

PTN 2.0 TO #11: CUDDLE 2.0

ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2024

PRECISE Study (Precision Biologics in Rheumatology)

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2021 - 2024

Optimizing Hydroxychloroquine to Reduce Disease Activity in Pediatric Lupus

ResearchMentor · Awarded by Thrasher Research Fund · 2021 - 2023

Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2021 - 2026

Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025

PTN 2.0 TO #11: CUDDLE 2.0

ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2024

PRECISE Study (Precision Biologics in Rheumatology)

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2021 - 2024

Optimizing Hydroxychloroquine to Reduce Disease Activity in Pediatric Lupus

ResearchMentor · Awarded by Thrasher Research Fund · 2021 - 2023

PTN 2.0 TO#4 BPCA Data Closeout and Dissemination - Option 4

ResearchPrincipal Investigator · Awarded by National Institute for Child Health & Human Develo · 2022 - 2023

Global Pediatric Clinical Trials Network

ResearchCo Investigator · Awarded by Food and Drug Administration · 2017 - 2023

PTN2- TO# BPCA Pharmacology Studies

ResearchCo Investigator · Awarded by National Institute for Child Health & Human Develo · 2018 - 2023

Vamorolone in Juvenile Autoimmune Myositis

Clinical TrialCo Investigator · Awarded by Cure JM Foundation · 2020 - 2022

PTN 2.0- TO#4/Option 3 Data Closeout and Dissemination

ResearchPrincipal Investigator · Awarded by National Institute for Child Health & Human Develo · 2021 - 2022

CARRA Registry Assistant Scientific Director

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2021 - 2022

OxyContin Pediatric PMR Study

ResearchPrincipal Investigator · Awarded by Purdue Pharma · 2022 - 2022

RTOP 18-0006 Option 1 / Protocol Implementation

Clinical TrialSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2022

RTOP 18-0006 Option 1 / Protocol Implementation

Clinical TrialMedical Monitor · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2021

HCQ Pharmacokinetics in Pediatric Lupus

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2019 - 2020

PTN2- TO# Data Closeout and Dissemination

ResearchCo Investigator · Awarded by National Institute for Child Health & Human Develo · 2018 - 2019

ACR/Amgen Rheumatology Fellowship Training Award

FellowshipFellow · Awarded by Rheumatology Research Foundation · 2015 - 2016

External Relationships


  • NIH
  • Patient Centered Outcomes Research Institute
  • Rutgers University
  • The Childhood Arthritis and Rheumatology Research Alliance (CARRA)
  • UCB Pharma
  • NIH
  • Patient Centered Outcomes Research Institute
  • Rutgers University
  • The Childhood Arthritis and Rheumatology Research Alliance (CARRA)
  • UCB Pharma
  • US Food and Drug Administration

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.